(NASDAQ: GOSS) Gossamer Bio's forecast annual revenue growth rate of -5.27% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.37%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.57%.
Gossamer Bio's revenue in 2025 is $124,590,000.On average, 5 Wall Street analysts forecast GOSS's revenue for 2025 to be $6,494,022,140, with the lowest GOSS revenue forecast at $2,248,018,165, and the highest GOSS revenue forecast at $13,592,667,972. On average, 4 Wall Street analysts forecast GOSS's revenue for 2026 to be $9,363,029,751, with the lowest GOSS revenue forecast at $3,789,126,674, and the highest GOSS revenue forecast at $19,297,951,686.
In 2027, GOSS is forecast to generate $26,536,842,939 in revenue, with the lowest revenue forecast at $11,860,625,665 and the highest revenue forecast at $49,665,517,590.